VYNE Therapeutics’ (VYNE) “Buy” Rating Reaffirmed at HC Wainwright

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $5.75 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 93.60% from the stock’s previous close.

Separately, BTIG Research began coverage on shares of VYNE Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $8.00 price target for the company.

VYNE Therapeutics Price Performance

Shares of NASDAQ VYNE opened at $2.97 on Monday. The company’s 50 day simple moving average is $2.71 and its 200 day simple moving average is $2.20. The firm has a market capitalization of $43.81 million, a P/E ratio of -3.45 and a beta of 1.37. VYNE Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $3.43.

Institutional Trading of VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics accounts for about 0.0% of Lynx1 Capital Management LP’s holdings, making the stock its 17th largest holding. Lynx1 Capital Management LP owned 0.11% of VYNE Therapeutics as of its most recent filing with the SEC. Institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.